Eli Lilly & Co. vs Vertex Pharmaceuticals Inc
LLY vs VRTX — side-by-side comparison from reported financials. LLY leads 7, VRTX leads 2 of 9 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Vertex Pharmaceuticals Inc
VRTX · Healthcare
$510.00+1.34%Mixed
| Metric | LLY | VRTX |
|---|---|---|
| Price | $1 177.20 | $510.00 |
| Market cap | $1.05T | $129B |
| Revenue (TTM) | $79.7B | $12.6B |
| Revenue growth | +31.7% | +10.3% |
| Net margin | 33.5% | 35.0% |
| Free cash flow | $18.2B | $3.80B |
| Net cash (debt) | ($35.2B) | — |
| 1-year price return | +37.6% | +22.9% |
| P/E | 41.6 | 29.3 |
| P/E vs own history (cheap-side %) | 88% | 29% |
| Dividend yield | 0.52% | — |
| Return on equity | 93% | 23% |
| Altman Z-score | 7.10 | — |
| CV checks passed | 11 of 11 | 9 of 11 |
| Employees | 50,000 | 6,400 |
Full résumé-style profiles: LLY CV · VRTX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.